NY-MORROW-SODALI
14.1.2020 12:02:06 CET | Business Wire | Press release
Morrow Sodali announced today that Debt Capital Markets industry experts Damian Watkin, Damir Hadžiosmanović, Ken Abela and Tina Siu, have joined the firm as part of a global strategy to strengthen its bonds-related services offering.
The team, which provides 50+ years of combined experience working on over 800 debt-related deals, joins Morrow Sodali from D.F. King and will be based in London and Hong Kong, bolstering the firm’s global presence in Debt Services. They will work alongside leading in-house expert Pia Gowland who from now on will oversee Morrow Sodali’s Debt Services activities in the Americas.
Damian Watkin, who joins Morrow Sodali as a Senior Director in the firm’s London office, brings 20 years’ experience in the capital markets industry working with global financial institutions, corporate and sovereign issuers, with extensive expertise in executing liability management and debt restructuring transactions and researching ownership in capital structures. In his previous role at D.F. King, Mr. Watkin built and led the firm’s bonds business outside of the US market, working with a broad range of debt issuers, and their advisors, in some of the largest or highest profile transactions of recent years.
“We are very excited to join the entrepreneurial and client-focused team at Morrow Sodali and be able to offer a seamless service from a truly global and technology-led execution platform to bond issuers and their advisers,” said Mr. Watkin. “Morrow Sodali now has a global footprint, with experienced execution professionals based in Asia, Europe and the Americas.”
Joining Mr. Watkin in London as a Director, Damir Hadžiosmanović has nearly 20 years’ experience in working with corporate and sovereign issuers, assisting them in executing various liability management transactions and bondholder identifications, as well as debt restructurings and schemes of arrangement.
Ken Abela, who joins Morrow Sodali as a Director, brings nearly 20 years’ experience, of which 17 years in Asia, in assisting corporate and sovereign issuers in executing liability management and debt restructuring transactions. Mr. Abela will be based in Hong Kong and will be responsible for strengthening the firm’s Debt Services offering across Asia Pacific markets.
“We are looking forward to expanding Morrow Sodali’s debt-related services in Asia, providing bond issuers and their advisors in the region with an experienced local point of contact, with the ability to assist with transactions and provide advice to practitioners in their own time zone,” said Mr. Abela.
Joining Mr. Abela in Hong Kong, Tina Siu has assisted in providing D.F. King’s debt-related activities led by Mr. Abela, with a strong track record of supporting bond issuers in executing liability management transactions across Asian markets. Prior to D.F. King, Ms. Siu worked with financial institutions focusing on debt market research as well as conducting financial analysis for corporate clients.
Morrow Sodali Global Corporate Director Giulio Pediconi commented: “We are delighted to welcome such an experienced team within the Morrow Sodali family. With the global expansion of corporate debt markets, our combined expertise across our dedicated hubs in New York, London and Hong Kong will enable us to expand our services and offer our clients a truly global coverage in this key market.”
About Morrow Sodali
Morrow Sodali is a leading provider of strategic advice and shareholder and bondholder services to corporate and sovereign clients around the world. The firm provides corporate boards and executives with strategic advice and services relating to corporate governance, shareholder and bondholder communication and engagement, capital markets intelligence, proxy solicitation, shareholder activism, mergers and acquisitions and debt-related transactions.
From headquarters in New York and London, and offices and partners in major capital markets, Morrow Sodali serves more than 700 corporate clients in 40 countries, including many of the world’s largest multinational corporations. In addition to listed and private companies, its clients include mutual funds, ETFs, stock exchanges and membership associations.
For further information about Morrow Sodali, please visit www.morrowsodali.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom